Literature DB >> 12734923

Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis.

Gayatri Mittal, Zarir Udwadia, Vinay R Joshi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12734923

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  4 in total

1.  Effect of mycophenolate sodium in scleroderma-related interstitial lung disease.

Authors:  Carmen Pilar Simeón-Aznar; Vicent Fonollosa-Plá; Carles Tolosa-Vilella; Albert Selva-O'Callaghan; Roser Solans-Laqué; Miquel Vilardell-Tarrés
Journal:  Clin Rheumatol       Date:  2011-09-01       Impact factor: 2.980

2.  Improvement of lung function in patients with systemic sclerosis after 6 months cyclophosphamide pulse therapy.

Authors:  Predrag Ostojic; Nemanja Damjanov
Journal:  Clin Rheumatol       Date:  2006-01-27       Impact factor: 2.980

3.  Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function.

Authors:  W M T van den Hombergh; S O Simons; E Teesselink; H K A Knaapen-Hans; F H J van den Hoogen; J Fransen; M C Vonk
Journal:  Clin Rheumatol       Date:  2018-07-10       Impact factor: 2.980

4.  Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis-related interstitial lung disease: a long term study.

Authors:  C P Simeón-Aznar; V Fonollosa-Plá; C Tolosa-Vilella; A Selva-O Callaghan; R Solans-Laqué; E Palliza; X Muñoz; M Vilardell-Tarrés
Journal:  Open Respir Med J       Date:  2008-05-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.